These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11320680)

  • 21. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
    Edwards JG; Anderson I
    Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in antidepressant overdoses.
    McKenzie MS; McFarland BH
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):513-23. PubMed ID: 17200994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics.
    Goldstein BJ; Goodnick PJ
    J Psychopharmacol; 1998; 12(3 Suppl B):S55-87. PubMed ID: 9808079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid and Benzodiazepine Substitutes: Impact on Drug Overdose Mortality in Medicare Population.
    Kuo YF; Liaw V; Yu X; Raji MA
    Am J Med; 2022 Jul; 135(7):e194-e206. PubMed ID: 35341773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Selective serotonin uptake inhibitors and pancreatitis].
    Kvande KT; Madsen S
    Tidsskr Nor Laegeforen; 2001 Jan; 121(2):177-8. PubMed ID: 11475194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.
    Rodriguez de la Torre B; Dreher J; Malevany I; Bagli M; Kolbinger M; Omran H; Lüderitz B; Rao ML
    Ther Drug Monit; 2001 Aug; 23(4):435-40. PubMed ID: 11477329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
    Hedenmalm K; Güzey C; Dahl ML; Yue QY; Spigset O
    J Clin Psychopharmacol; 2006 Apr; 26(2):192-7. PubMed ID: 16633151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system.
    Spigset O
    Drug Saf; 1999 Mar; 20(3):277-87. PubMed ID: 10221856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports.
    Schillevoort I; van Puijenbroek EP; de Boer A; Roos RA; Jansen PA; Leufkens HG
    Int Clin Psychopharmacol; 2002 Mar; 17(2):75-9. PubMed ID: 11892721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors.
    Peretti S; Judge R; Hindmarch I
    Acta Psychiatr Scand Suppl; 2000; 403():17-25. PubMed ID: 11019931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association.
    Vilhelmsson A; Svensson T; Meeuwisse A; Carlsten A
    BMC Clin Pharmacol; 2011 Oct; 11():16. PubMed ID: 22026961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability.
    Qin B; Zhang Y; Zhou X; Cheng P; Liu Y; Chen J; Fu Y; Luo Q; Xie P
    Clin Ther; 2014 Jul; 36(7):1087-1095.e4. PubMed ID: 24998011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.
    Trenque T; Maura G; Herlem E; Vallet C; Sole E; Auriche P; Drame M
    Drug Saf; 2013 Jul; 36(7):515-9. PubMed ID: 23728950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the use of SSRIs reduce medical care utilization and expenditures?
    Chung S
    J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
    Montastruc F; Sommet A; Bondon-Guitton E; Durrieu G; Bui E; Bagheri H; Lapeyre-Mestre M; Schmitt L; Montastruc JL
    Eur J Clin Pharmacol; 2012 May; 68(5):767-75. PubMed ID: 22116460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective serotonin reuptake inhibitors for premenstrual syndrome.
    Marjoribanks J; Brown J; O'Brien PM; Wyatt K
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD001396. PubMed ID: 23744611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures.
    Ziere G; Dieleman JP; van der Cammen TJ; Hofman A; Pols HA; Stricker BH
    J Clin Psychopharmacol; 2008 Aug; 28(4):411-7. PubMed ID: 18626268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics.
    Prescrire Int; 2001 Feb; 10(51):25-31. PubMed ID: 11503857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.